Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (1465)	2/25/2000 10:58:00 AM
From: nigel bates	Read Replies (1) \| Respond to of 4974

In addition to TTP and OGS today ... NEW HAVEN, Conn., Feb. 25 /PRNewswire/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN - news) today announced that it intends to offer, subject to market and other conditions, approximately $120 million of Convertible Subordinated Notes due 2007 ($150 million if an option for an additional $30 million is exercised in full) ViroPharma Incorporated today announced that it has increased its previously announced private placement of Convertible Subordinated Notes due 2007 to $150 million (up from $100 million) and has priced the offering. The offering, which was made through initial purchasers to qualified institutional buyers under Rule 144 A of the Securities Act of 1933 and to a limited number of institutional accredited investors, is expected to close on March 1, 2000. The notes are convertible into shares of ViroPharma common stock at a price of $109.15 per share, subject to certain adjustments. ViroPharma also has granted the initial purchasers of the notes an option to purchase up to an additional $30 million in principal amount of the notes. The notes will bear interest at a rate of 6 percent per annum, have a 7-year term, and can be redeemed by ViroPharma, at certain premiums over the principal amount, at any time after March 6, 2003. UNIONDALE, N.Y., Feb. 25 /PRNewswire/ -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP - news) announced today that it has entered into definitive purchase agreements to raise $56 million in gross proceeds through a private sale of 3.325 million newly-issued shares of its common stock to a select group of institutional investors. cash is flowing... nig